STOCKWATCH

Cohance Lifesciences to Infuse USD 10 Million in Subsidiary NJ Bio Inc.

Cohance Lifesciences Ltd. has announced its decision to infuse funds into its subsidiary, NJ Bio Inc., based in the USA. The fund infusion, amounting to USD 10 million, will be made by way of investment in Compulsorily Convertible Preferred Stock. The funds, when deployed, will support the subsidiary's growth initiatives, including capital expenditure (capex). The details of this transaction will be disclosed to the stock exchange(s) after the approval of the Board of NJ Bio Inc.

• Cohance Lifesciences to invest USD 10 million in its subsidiary, NJ Bio Inc.
• Investment to be made in Compulsorily Convertible Preferred Stock.
• Funds to support subsidiary's growth initiatives and capex.
• Details of the transaction to be disclosed to the stock exchange(s) after approval of NJ Bio Inc.'s Board.